Compliance of price fixation of coronary stents and related issues

NPPA had notified the ceiling prices of Coronary Stents vide SO.No. 412 (E) dated 13.02.2017. Further, NPPA has issued subsequent clarifications vide Office Memorandums requesting all manufacturers/importers/marketers of coronary stents and the hospitals to comply with the notified ceiling price of stents and to adhere to all the instructions issued so far in letter and spirit.

NPPA has informed all hospitals, doctors and patients that if there is any shortage of the following specified stents viz. Resolute Onyx Zotarolimus Eluting Coronary Stent System (M/s India Medtronic Pvt. Ltd), Absorb GTI-Bioresorbable Vascular Scaffold (BVS), (M/s Abbott Healthcare Pvt. Ltd.), XIence Alpine Medical Device [Cardiac stent] (M/s Abbott Healthcare Pvt. Ltd.), SYNERGY ™ monorail Everolimus–Eluting Platinum Chromium Coronary Stent System with biodegradable polymer, Promus PREMIER ™ Everolimus–Eluting Coronary Stent System (M/s Boston Scientific India Private Limited), they should inform NPPA immediately about such shortage through any one of the following means:

i. Call NPPA’s toll free number 1800111255
ii. Lodge a complaint through grievance redressal system “PHARMA JAN SAMADHAN” by visiting the website of NPPA at “www.nppaindia.nic.in”
iii. Message the complaint through WhatsApp on Mobile number 9958217773

NPPA will initiate action on priority basis to ensure the availability of stents at places where the shortage was reported.

NPPA has requested to all SDC’s to carry out checks to ensure that the following specified stents viz. Resolute Onyx Zotarolimus Eluting Coronary Stent System, Absorb GTI-Bioresorbable Vascular Scaffold (BVS), Xience Alpine Medical Device [Cardiac stent], SYNERGY ™ monorail Everolimus–Eluting Platinum Chromium Coronary Stent System with biodegradable polymer, Promus PREMIER ™ Everolimus–Eluting Coronary Stent System are available in hospitals and with distributors. NPPA has asked them to carry out necessary inspections if required at place of business of stent companies/distributors/hospitals under Para 30 of DPCO 2013 and take necessary action.